Nefazodone in community use: The results of prescription-event monitoring

Pharmacoepidemiology and Drug Safety

Volumn 8, Issue 4, 1999, Pages 267-273

  Mackay, F J ^b   Pearce, G L ^a   Freemantle, S N ^a   Mann, R D ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b Bursledon Hall ^*

Author keywords

Elderly; Nefazodone; Pharmacovigilance; Pregnancy; Prescription Event Monitoring

Indexed keywords

FLUOXETINE; FLUVOXAMINE; NEFAZODONE; PAROXETINE; SERTRALINE;

ADOLESCENT; ADULT; AGED; ANXIETY NEUROSIS; ARTICLE; COHORT ANALYSIS; COMMUNITY CARE; DEPRESSION; DROWSINESS; DRUG FATALITY; DRUG MONITORING; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; DRUG USE; FALLING; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; INVOLUNTARY MOVEMENT; KIDNEY DISEASE; LIVER DISEASE; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; NAUSEA; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; THROMBOCYTOPENIA; UNITED KINGDOM; VERTIGO; WITHDRAWAL SYNDROME;

EID: 0032803835     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199907)8:4<267::AID-PDS423>3.0.CO;2-K     Document Type: Article

References (15)

1. Summary of Product Characteristics. Dutonin (nefazodone). Bristol-Myers Squibb Pharmaceuticals Ltd October 1995. In ABPI Compendium of Data Sheets and Summaries of Product Characteristics. Datapharm Publications Ltd, 1996-7, 175-176.
2. Committee on Safety of Medicines. InAdverse Drug Reactions. Ed. Mann, R. D., Parthenon Publishing, Carnforth, UK, 1987, pp 62-63.
3. Mackay, F., Dunn, N., Wilton, L., Pearce, G., Freemantle, S. and Mann, R. D. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol. Drug Saf. 1997; 6: 235-246.
4. Mann, R. D., Wilton, L. V., Pearce, G. L., Mackay, F. J. and Dunn, N. R. Prescription-event monitoring (PEM) in 1996 - a method of noninterventional observational cohort pharmacovigilance. Pharmacoepidemiol. Drug Saf. 1997; 6(supplement 3): S5-S11.
5. Mann, R. D. Prescription-event monitoring -recent progress and future horizons. Br. J. Clin. Pharmacol. 1998; 46: 195-201.
6. Council for International Organisations of Medical Sciences/World Health Organisation, Geneva. International Ethical Guidelines for Biochemical Research Involving Human Subjects, WHO, Geneva, 1993.
7. Sporer, K. A. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 1995; 13(2): 94-104.
8. Paykel, E. S. and Priest, R. G. Recognition and management of depression in general practice: consensus statement. Br. Med. J. 1992; 305: 1198-1202.
9. Priest, R. G., Vize, C., Roberts, A., Roberts, M. and Tylee, A. Lay people's attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. Br. Med. J. 1996; 313: 858-859.
10. Martin, R., Hilton, S. and Richards, N. Reasons for stopping drugs could be recorded in general practice. Br. Med. J. 1996; 312: 1418-1419.
11. Coulter, D. M. Reasons for stopping drugs are monitored in New Zealand. Br. Med. J. 1996; 313: 756.
12. Tinetti, M. E., Baker, D. I., McAvay, M. S., et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N. Engl. J. Med. 1994; 331: 821-827.
13. George, C. F. and Robertson, D. Clinical consequences of abrupt drug withdrawal. Med. Toxicol. 1987; 2: 367-382.
14. British National Formulary, 35, British Medical Association and Royal Pharmaceutical Society of Great Britain, 1998: 176, 183 and 185.
15. Kulin, N., Pastuszak, A., Sage, S. R., et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. A prospective controlled multicentre study. JAMA 1998; 279(8): 609-610.